Skip to main content
VaccineWatch
VaccinesSymptomsStatesAnalysisToolsDashboardCompare

VaccineWatch

Transparent access to VAERS data for informed decision-making. We present the data as-is, with appropriate context and disclaimers.

Explore Data

  • Vaccines
  • Symptoms
  • Manufacturers
  • States
  • Dashboard
  • Compare Tool
  • Search

Deep Dives

  • The Denominator Problem
  • Onset Timing
  • Lot Number Analysis
  • COVID Impact
  • Myocarditis
  • Death Reports
  • Interactive Tools
  • All 23 Articles →

Resources

  • About
  • Methodology
  • FAQ
  • Glossary
  • Side Effects Guide
  • Vaccine Schedule
  • Vaccine Safety
  • Safety Timeline
  • Adverse Events
  • Is VAERS Reliable?
  • Report an Event
  • Disclaimer
  • VAERS Official Site ↗

Sister Sites

  • OpenMedicaid
  • OpenFeds
  • OpenSpending
  • OpenMedicare
  • OpenLobby
  • TheDataProject.ai

Data source: VAERS (Vaccine Adverse Event Reporting System)

Data through 2026 · Updated quarterly

Built by TheDataProject.ai · © 2026 VaccineWatch

Important: VAERS accepts reports of adverse events following vaccination. For any given report, there is no certainty that the reported event was caused by the vaccine. Reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. Most reports to VAERS are voluntary, which means they are subject to biases. This data cannot be used to determine if vaccines cause or contribute to adverse events.

⚠️

Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.

  1. Home
  2. Vaccines
  3. Zoster Live (Zostavax)
  4. Urinary tract infection
Zoster Live (Zostavax)×Urinary tract infection

Urinary tract infection Reports for Zoster Live (Zostavax)

#338 most reported symptom for this vaccine

115
Reports
7
Deaths
35
Hospitalizations
6.09
Mortality Rate
%
30.4
Hosp. Rate
%

Urinary tract infection and Zoster Live (Zostavax)

Urinary tract infection has been reported 115 times in association with Zoster Live (Zostavax) vaccination in VAERS. This represents 0.1% of all 140,312 reports for this vaccine.

Among these reports, 7 mentioned death (6.09%) and 35 involved hospitalization (30.4%).

Urinary tract infection is the #338 most frequently reported symptom for Zoster Live (Zostavax) out of 2827 total symptoms.

Disclaimer: VAERS reports describe events that occurred after vaccination but do not establish that the vaccine caused the event. Many reported symptoms may be coincidental or related to underlying conditions.

What This Means

Seeing 115 reports of Urinary tract infection after Zoster Live (Zostavax) vaccination may seem alarming, but context is critical. With 140,312 total reports for this vaccine (representing many millions of doses), Urinary tract infection appears in only 0.1% of reports.

The 6.09% mortality rate among these reports is elevated, but this reflects the severity of the condition itself rather than vaccine causation.

Important Context

•Association, not causation: These reports show Urinary tract infection occurred after vaccination, not that the vaccine caused it.
•Background rates: Urinary tract infection may occur naturally at baseline rates in the population, unrelated to vaccination.
•Anyone can report: VAERS accepts reports from anyone — patients, parents, healthcare providers — without requiring medical verification.
•Denominator missing: VAERS counts reports, not rates per dose. Without knowing how many doses were given, raw counts can be misleading. Learn more →

Similarly Ranked Symptoms

Presyncope116 reportsRestlessness116 reportsDyskinesia115 reportsSecretion discharge115 reports

Quick Facts

Reports:115
Deaths:7
Hospitalizations:35
% of Vaccine:0.1%
Rank:#338 of 2827

Related Pages

Zoster Live (Zostavax) OverviewUrinary tract infection (All Vaccines)Why Raw Numbers MisleadTop Symptoms Analysis

Data Source

This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.